Visual Hallucinations in Lewy Body Dementia

Core Features and Diagnosis

The American Academy of Neurology suggests that other core features of Lewy body dementia include fluctuating cognition with variations in attention, REM sleep behavior disorder (RBD), and parkinsonism 1, 2

Charles Bonnet Syndrome (CBS) can also cause visual hallucinations but is characterized by hallucinations with preserved insight, no other neurological explanation, and some degree of vision loss, according to the American Academy of Ophthalmology 3, 2
DLB hallucinations differ from CBS in that they are often associated with other neurological symptoms and may persist despite patient education, as noted by the American Academy of Ophthalmology 3

The International Association for Alzheimer's and Dementia recommends that patients experiencing unexplained visual hallucinations, especially when combined with fluctuating cognition, should be evaluated for possible DLB 4, 5

The American Geriatrics Society suggests that patient and caregiver education about the nature of hallucinations can significantly reduce anxiety and fear 2
Simple coping strategies like eye movements, changing lighting, or distraction techniques can be effective in managing hallucinations, as recommended by the American Geriatrics Society 2
The American Academy of Neurology notes that Rivastigmine has demonstrated efficacy in treating visual hallucinations in DLB 2
Regular monitoring using appropriate scales such as the Neuropsychiatric Inventory (NPI) can help assess hallucination progression, according to the International Psychogeriatric Association 2

Cholinesterase inhibitors should be continued even if cognitive and functional decline progresses, as long as they provide meaningful reduction in hallucinations, according to the Alzheimer's and Dementia guidelines 6, 7
Do not discontinue cholinesterase inhibitors in patients with clinically meaningful psychotic symptoms until these symptoms have stabilized, as recommended by the Alzheimer's and Dementia guidelines 6, 7
If discontinuation is necessary for other reasons, taper gradually by reducing dose by 50% every 4 weeks until reaching the initial starting dose, then discontinue after 4 more weeks, as suggested by the Alzheimer's and Dementia guidelines 7
Reinitiate treatment if clinically meaningful worsening of neuropsychiatric symptoms occurs after discontinuation, according to the Alzheimer's and Dementia guidelines 7

The American Geriatrics Society recommends evaluating for delirium, infections, dehydration, pain, fecal impaction, medication adverse effects, and metabolic disturbances before attributing hallucinations to dementia alone 8
A comprehensive metabolic panel, thyroid function tests, B12, folate, liver function tests, complete blood count, vital signs, and urinalysis should be performed to rule out reversible causes 9
Non-pharmacological treatments should be the initial approach when there are no psychotic features causing severe distress and no immediate danger to the patient or others, according to the American Geriatrics Society 8
Music therapy has been shown to reduce depression, anxiety, and overall behavioral problems in patients with dementia, with evidence from the Alzheimer's and Dementia journal 10
Reminiscence therapy provides structured recall of past experiences and is an effective non-pharmacological intervention for patients with dementia, as reported in the Alzheimer's and Dementia journal 11

The American Geriatrics Society suggests considering pharmacological treatment if non-pharmacological interventions fail after 30 days, or if severe hallucinations with psychotic features cause significant distress 8
Cholinesterase inhibitors, particularly rivastigmine, are the preferred pharmacological agents for treating visual hallucinations in dementia, with evidence from the Mayo Clinic Proceedings 9
Antipsychotics should be used with extreme caution due to the increased risk of mortality in elderly patients with dementia-related psychosis, and should only be considered for severe behavioral symptoms with psychotic features when other treatments have failed, according to the American Geriatrics Society 8

The American Geriatrics Society recommends evaluating pharmacological treatments for tapering or discontinuation within 6 months after symptoms stabilize, and attempting tapering every 6 months thereafter 8

Optimizing ambient lighting levels in the living environment of patients with Dementia with Lewy Bodies helps reduce confusion and restlessness associated with visual hallucinations. 12

Removing or shielding windows and mirrors to avoid glare decreases visual ambiguity and can lessen the frequency of hallucination episodes in Dementia with Lewy Bodies. 12